Omeros (NASDAQ:OMER) Shares Down 4.4% – What’s Next?

Omeros Co. (NASDAQ:OMER) dropped 4.4% during mid-day trading on Friday . The stock traded as low as $8.66 and last traded at $8.61. Approximately 99,645 shares changed hands during trading, a decline of 83% from the average daily volume of 578,914 shares. The stock had previously closed at $9.01.

Analysts Set New Price Targets

OMER has been the subject of several analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a report on Friday, January 17th. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a report on Thursday, November 14th. StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. D. Boral Capital reiterated a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Thursday, January 16th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Performance

The stock’s 50-day moving average price is $9.65 and its 200-day moving average price is $6.13. The company has a market capitalization of $481.10 million, a price-to-earnings ratio of -3.58 and a beta of 2.01.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. purchased a new position in shares of Omeros during the 4th quarter worth approximately $121,000. BNP Paribas Financial Markets increased its stake in shares of Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares in the last quarter. Seros Financial LLC purchased a new position in shares of Omeros during the 4th quarter worth approximately $159,000. MML Investors Services LLC increased its stake in shares of Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 3,000 shares in the last quarter. Finally, SPC Financial Inc. purchased a new position in shares of Omeros during the 3rd quarter worth approximately $77,000. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.